BaroFold Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron™

BaroFold Inc. has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of BaroFeron™ (IFNß-1b).

In published preclinical studies BaroFeron demonstrated enhanced pharmacological properties, both pharmacokinetics and pharmacodynamics, when compared to commercial interferon beta products.

aroFeron has the potential to offer significant benefits to multiple sclerosis patients as these properties have been demonstrated to correlate with lesion formation by MRI measurements and clinical exacerbations.

“BaroFeron is posed to set a new standard for biologics incorporating our novel PreEMT™ technology that produces a product with biopharmaceutical properties that may be superior to conventionally produced proteins,” stated Jeffrey L. Cleland, Ph.D., Vice President of Therapeutic Development. “We believe that MS patients will ultimately benefit from the unique properties of BaroFeron.”